AstraZeneca says that treme flubbed another combo cancer study, raising fresh doubts about a serial loser
AstraZeneca’s badly damaged CTLA-4 strategy on the immuno-oncology front has taken another hit.
The pharma giant put out word that the second leg of its CASPIAN study failed to demonstrate a significantly improved rate of overall survival among patients given a triplet of Imfinzi, standard of care and the CTLA-4 tremelimumab among frontline small cell lung cancer patients with extensive disease.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,500+ biopharma pros reading Endpoints daily — and it's free.